rs80224560
Cystic Fibrosis related |
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(A;A) | 5 | Cystic Fibrosis; possibly a mild form (see discussion) |
(A;G) | 3 | Cystic Fibrosis carrier |
(G;G) | 0 | common in clinvar |
Reference | GRCh38 38.1/141 |
Chromosome | 7 |
Position | 117602868 |
Gene | CFTR |
is a | snp |
is | mentioned by |
dbSNP | rs80224560 |
dbSNP (classic) | rs80224560 |
ClinGen | rs80224560 |
ebi | rs80224560 |
HLI | rs80224560 |
Exac | rs80224560 |
Gnomad | rs80224560 |
Varsome | rs80224560 |
LitVar | rs80224560 |
Map | rs80224560 |
PheGenI | rs80224560 |
Biobank | rs80224560 |
1000 genomes | rs80224560 |
hgdp | rs80224560 |
ensembl | rs80224560 |
geneview | rs80224560 |
scholar | rs80224560 |
rs80224560 | |
pharmgkb | rs80224560 |
gwascentral | rs80224560 |
openSNP | rs80224560 |
23andMe | rs80224560 |
SNPshot | rs80224560 |
SNPdbe | rs80224560 |
MSV3d | rs80224560 |
GWAS Ctlg | rs80224560 |
Max Magnitude | 5 |
rs80224560, probably best known as 2789+5G>A, is a mutation in the cystic fibrosis CFTR gene. It has been reported as leading to a relatively mild form of cystic fibrosis; see the discussion at I4000320.
also named i5011620 by 23andMe
ClinVar | |
---|---|
Risk | Rs80224560(A;A) |
Alt | Rs80224560(A;A) |
Reference | Rs80224560(G;G) |
Significance | Pathogenic |
Disease | Cystic fibrosis Hereditary pancreatitis not provided |
Variation | info |
Gene | CFTR |
CLNDBN | Cystic fibrosis Hereditary pancreatitis not provided |
Reversed | 0 |
HGVS | NC_000007.13:g.117242922G>A |
CLNSRC | CFTR2 |
CLNACC | RCV000043564.5, RCV000366376.1, RCV000487256.1, |
[PMID 1867511] [Renal abscess. Medical treatment].
[PMID 12007216] Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.
[PMID 15371902] Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
[PMID 15371903] CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.